LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Elenco Azioni・Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

Chiusa

SettoreSettore sanitario

492.82 1.27

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

491.57

Massimo

495.72

Metriche Chiave
By Trading Economics
Entrata	-314M 1.7B
Vendite	-1.2B 11B
P/E Media del settore	24.631 50.102
EPS	5.44
Rendimento da dividendi	0.39
Margine di Profitto	15.048
Dipendenti	125,000
EBITDA	-905M 2.3B

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+25.87% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	0.39% 2.33%
Utili prossimi	22 lug 2026
Prossima data del Dividendo	15 lug 2026
Prossima data del' Ex Dividendo	15 giu 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-29B 167B
Apertura precedente	491.55
Chiusura precedente	492.82

Notizie sul Sentiment di mercato

By Acuity

35%

65%

96 / 344 Classifica in Healthcare

Thermo Fisher Scientific Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 apr 2026, 13:56 UTC

Utili

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

23 apr 2026, 10:28 UTC

Utili

Thermo Fisher Posts Higher 1Q Profit, Revenue

29 gen 2026, 11:34 UTC

Utili

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29 ott 2025, 10:51 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23 ott 2025, 20:49 UTC

Utili

Correction to Thermo Fisher Article on Oct. 22

22 ott 2025, 10:28 UTC

Utili

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

15 mag 2026, 10:45 UTC

Discorsi di Mercato

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

23 apr 2026, 10:01 UTC

Utili

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23 apr 2026, 10:01 UTC

Utili

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

23 apr 2026, 10:00 UTC

Utili

Thermo Fisher 1Q Net $1.65B >TMO

23 apr 2026, 10:00 UTC

Utili

Thermo Fisher 1Q Adj EPS $5.44 >TMO

23 apr 2026, 10:00 UTC

Utili

Thermo Fisher 1Q EPS $4.43 >TMO

23 apr 2026, 10:00 UTC

Utili

Thermo Fisher 1Q Rev $11.01B >TMO

24 mar 2026, 12:04 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24 mar 2026, 12:00 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29 gen 2026, 11:01 UTC

Utili

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher 4Q Net $1.96B >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher 4Q Rev $12.22B >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher 4Q EPS $5.21 >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29 ott 2025, 10:06 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29 ott 2025, 10:05 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29 ott 2025, 10:05 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29 ott 2025, 10:04 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29 ott 2025, 10:00 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22 ott 2025, 10:01 UTC

Utili

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22 ott 2025, 10:00 UTC

Utili

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22 ott 2025, 10:00 UTC

Utili

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22 ott 2025, 10:00 UTC

Utili

Thermo Fisher 3Q Rev $11.12B >TMO

Confronto tra pari

Modifica del prezzo

Thermo Fisher Scientific Inc Previsione

Obiettivo di Prezzo

By TipRanks

25.87% in crescita

Previsioni per 12 mesi

Media 613.27 USD 25.87%

Alto 685 USD

Basso 490 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Thermo Fisher Scientific Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 18 che hanno fornito valutazioni azionarie a Thermo Fisher Scientific Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

96 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar